<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02275065</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-141-1219</org_study_id>
    <nct_id>NCT02275065</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Bictegravir (GS-9883) in Human Immunodeficiency Virus (HIV)-1 Infected Participants</brief_title>
  <official_title>A Phase 1b Randomized, Double-Blinded, Sequential Cohort Placebo-Controlled Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to investigate the short-term antiviral potency of&#xD;
      bictegravir at multiple doses in antiretroviral (ART) treatment-naive adult participants and&#xD;
      participants who are ART-experienced but integrase strand transfer inhibitor (INSTI) naive.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 24, 2014</start_date>
  <completion_date type="Actual">January 29, 2015</completion_date>
  <primary_completion_date type="Actual">January 23, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time-Weighted Average Change From Baseline up to Day 11 (DAVG11) in Plasma HIV-1 RNA</measure>
    <time_frame>Baseline up to Day 11</time_frame>
    <description>DAVG11 was defined as the time-weighted average between the first postbaseline value through the last available on-treatment (ie, the last dose date + 1) value up to Day 11 minus the baseline value in plasma HIV-1 RNA (log10 copies/mL). All HIV-1 RNA data up to Day 11 were used for this analysis. DAVG11 was calculated using the trapezoidal rule and the area-under-the-curve concept.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (AEs)</measure>
    <time_frame>First dose date up to last dose date plus 30 days (Maximum: 40 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experienced Graded Laboratory Abnormalities</measure>
    <time_frame>First dose date up to last dose date plus 30 days (Maximum: 40 days)</time_frame>
    <description>A treatment-emergent graded laboratory abnormality was defined as an increase of at least 1 toxicity grade from predose assessment and occurring after the predose visit and on or before the date of the last dose of study drug plus 30 days. If the predose assessment was missing, then any abnormality of at least Grade 1 associated with the study drug was considered a treatment-emergent graded laboratory abnormality. The most severe graded abnormality from all tests was counted for each participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Reduction From Baseline Through Day 17 in Plasma HIV-1 RNA</measure>
    <time_frame>Baseline to Day 17</time_frame>
    <description>Maximum reduction from baseline was defined as the minimum of change from baseline in plasma HIV-1 RNA (i.e. smallest change in HIV-RNA from baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral Decay Slope in Plasma HIV-1 RNA</measure>
    <time_frame>Baseline up to Day 11</time_frame>
    <description>Viral Decay Slope = (log10 [HIV-1 RNA on Day x] - log10 [HIV-1 RNA on Day 1]) / (x-1), where x is the collection day of the last available on treatment HIV-1 RNA collected up to Day 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL</measure>
    <time_frame>Day 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Parameter: Cmax of Bictegravir Following Single-Dose and Multiple-Dose Administration</measure>
    <time_frame>0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 1 for single dose and Day 10 for multiple dose</time_frame>
    <description>Cmax is defined as the maximum concentration of drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Tmax of Bictegravir Following Single-Dose and Multiple-Dose Administration</measure>
    <time_frame>0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 1 for single dose and Day 10 for multiple dose</time_frame>
    <description>Tmax is defined as the time (observed time point) of Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: AUC0-24 of Bictegravir Following Single-Dose Administration</measure>
    <time_frame>0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 1</time_frame>
    <description>AUC0-24 is defined as the concentration of drug over time from time zero to time 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: AUClast of Bictegravir Following Single-Dose Administration</measure>
    <time_frame>0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 1</time_frame>
    <description>AUClast is defined as the concentration of drug from time zero to the last observable concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: AUCtau of Bictegravir Following Multiple-Dose Administration</measure>
    <time_frame>0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 10</time_frame>
    <description>AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: t1/2 of Bictegravir Following Multiple-Dose Administration</measure>
    <time_frame>0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 10</time_frame>
    <description>t1/2 is defined as the estimate of the terminal elimination half-life of the drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Ctau of Bictegravir Following Multiple-Dose Administration</measure>
    <time_frame>0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 10</time_frame>
    <description>Ctau is defined as the observed drug concentration at the end of the dosing interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: CLss/F of Bictegravir Following Multiple-Dose Administration</measure>
    <time_frame>0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 10</time_frame>
    <description>CLss/F is defined as the apparent oral clearance following multiple-dose administration of the drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: AR_AUC of Bictegravir Following Multiple-Dose Administration</measure>
    <time_frame>0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 1 and 10</time_frame>
    <description>Accumulation ratio of AUC (AR_AUC) = AUCtau on Day 10 / AUC0-24 on Day 1. Percentage of accumulation ratio has been reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: AR_Cmax of Bictegravir Following Multiple-Dose Administration</measure>
    <time_frame>0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 1 and 10</time_frame>
    <description>Accumulation ratio of Cmax (AR_Cmax) = Cmax on Day 10 / Cmax on Day 1. Percentage of accumulation ratio has been reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK/Pharmacodynamic (PD) Analysis: Pearson Correlation Between AUCtau of Bictegravir and DAVG11 in Plasma HIV-1 RNA</measure>
    <time_frame>0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 10</time_frame>
    <description>AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval). DAVG11 was defined as the time-weighted average between the first postbaseline value through the last available on-treatment (ie, the last dose date + 1) value up to Day 11 minus the baseline value in plasma HIV-1 RNA (log10 copies/mL).</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>Bictegravir 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bictegravir 5 mg (1 Ã— 5 mg tablet) for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bictegravir 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bictegravir 25 mg (1 Ã— 25 mg tablet) for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bictegravir 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bictegravir 50 mg (2 Ã— 25 mg tablets) for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bictegravir 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bictegravir 100 mg (1 Ã— 100 mg tablet) for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matched to bictegravir tablet for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bictegravir</intervention_name>
    <description>Bictegravir tablet(s) administered orally once daily</description>
    <arm_group_label>Bictegravir 100 mg</arm_group_label>
    <arm_group_label>Bictegravir 25 mg</arm_group_label>
    <arm_group_label>Bictegravir 5 mg</arm_group_label>
    <arm_group_label>Bictegravir 50 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match bictegravir administered orally once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  No current or prior anti-HIV treatment, including ART medications received for&#xD;
             prevention (preexposure prophylaxis [PrEP]), or postexposure prophylaxis (PEP) within&#xD;
             12 weeks of screening&#xD;
&#xD;
          -  Plasma HIV-1 ribonucleic acid (RNA) â‰¥ 10,000 copies/mL but â‰¤ 400,000 copies/mL at&#xD;
             screening&#xD;
&#xD;
          -  Cluster of differentiation 4+ (CD4+) cell count &gt; 200 cells/mm^3&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Anticipated to start HIV-1 therapy during the study period&#xD;
&#xD;
          -  Active participation in another study of investigational or approved ART agents&#xD;
&#xD;
          -  A new acquired immunodeficiency syndrome (AIDS)-defining condition diagnosed within&#xD;
             the 30 days prior to screening&#xD;
&#xD;
          -  Participants with positive hepatitis C antibody at screening&#xD;
&#xD;
          -  Chronic hepatitis B virus (HBV) infection&#xD;
&#xD;
          -  Active, serious infections (other than HIV-1 infection) requiring parenteral&#xD;
             antibiotic or antifungal therapy within 42 days prior to Day 1 (baseline)&#xD;
&#xD;
        Note: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Davis</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berkley</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Fe</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 23, 2014</study_first_submitted>
  <study_first_submitted_qc>October 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2014</study_first_posted>
  <results_first_submitted>September 8, 2020</results_first_submitted>
  <results_first_submitted_qc>September 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 8, 2020</results_first_posted>
  <last_update_submitted>October 16, 2020</last_update_submitted>
  <last_update_submitted_qc>October 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV-1 Infected</keyword>
  <keyword>Adults</keyword>
  <keyword>Treatment Naive</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at study sites in United States. The first participant was screened on 24 October 2014. The last study visit occurred on 29 January 2015.</recruitment_details>
      <pre_assignment_details>33 participants were screened.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Bictegravir 5 mg</title>
          <description>Bictegravir 5 mg (1 Ã— 5 mg tablet) administered orally once daily for 10 days</description>
        </group>
        <group group_id="P2">
          <title>Bictegravir 25 mg</title>
          <description>Bictegravir 25 mg (1 Ã— 25 mg tablet) administered orally once daily for 10 days</description>
        </group>
        <group group_id="P3">
          <title>Bictegravir 50 mg</title>
          <description>Bictegravir 50 mg (2 Ã— 25 mg tablets) administered orally once daily for 10 days</description>
        </group>
        <group group_id="P4">
          <title>Bictegravir 100 mg</title>
          <description>Bictegravir 100 mg (1 Ã— 100 mg tablet) administered orally once daily for 10 days</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>Placebo matched to bictegravir tablet administered orally once daily for 10 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Randomized but not treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Safety Analysis Set included participants who were randomized and received at least 1 dose of bictegravir or matched placebo.</population>
      <group_list>
        <group group_id="B1">
          <title>Bictegravir 5 mg</title>
          <description>Bictegravir 5 mg (1 Ã— 5 mg tablet) administered orally once daily for 10 days</description>
        </group>
        <group group_id="B2">
          <title>Bictegravir 25 mg</title>
          <description>Bictegravir 25 mg (1 Ã— 25 mg tablet) administered orally once daily for 10 days</description>
        </group>
        <group group_id="B3">
          <title>Bictegravir 50 mg</title>
          <description>Bictegravir 50 mg (2 Ã— 25 mg tablets) administered orally once daily for 10 days</description>
        </group>
        <group group_id="B4">
          <title>Bictegravir 100 mg</title>
          <description>Bictegravir 100 mg (1 Ã— 100 mg tablet) administered orally once daily for 10 days</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>Placebo matched to bictegravir tablet administered orally once daily for 10 days</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="4"/>
            <count group_id="B5" value="4"/>
            <count group_id="B6" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29" spread="4.0"/>
                    <measurement group_id="B2" value="44" spread="16.5"/>
                    <measurement group_id="B3" value="34" spread="11.5"/>
                    <measurement group_id="B4" value="36" spread="11.2"/>
                    <measurement group_id="B5" value="24" spread="3.2"/>
                    <measurement group_id="B6" value="33" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Human Immunodeficiency Virus, Type 1 Ribonucleic Acid (HIV-1 RNA)</title>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.76" spread="1.020"/>
                    <measurement group_id="B2" value="4.64" spread="0.498"/>
                    <measurement group_id="B3" value="4.42" spread="0.458"/>
                    <measurement group_id="B4" value="4.71" spread="1.040"/>
                    <measurement group_id="B5" value="4.50" spread="0.407"/>
                    <measurement group_id="B6" value="4.40" spread="0.745"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time-Weighted Average Change From Baseline up to Day 11 (DAVG11) in Plasma HIV-1 RNA</title>
        <description>DAVG11 was defined as the time-weighted average between the first postbaseline value through the last available on-treatment (ie, the last dose date + 1) value up to Day 11 minus the baseline value in plasma HIV-1 RNA (log10 copies/mL). All HIV-1 RNA data up to Day 11 were used for this analysis. DAVG11 was calculated using the trapezoidal rule and the area-under-the-curve concept.</description>
        <time_frame>Baseline up to Day 11</time_frame>
        <population>The Per-Protocol Analysis Set included all randomized participants who took at least 1 dose of bictegravir with baseline HIV-1 RNA â‰¥ 1900 copies/mL, which allowed up to 2 log decreases in HIV-1 RNA.</population>
        <group_list>
          <group group_id="O1">
            <title>Bictegravir 5 mg</title>
            <description>Bictegravir 5 mg (1 Ã— 5 mg tablet) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Bictegravir 25 mg</title>
            <description>Bictegravir 25 mg (1 Ã— 25 mg tablet) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O3">
            <title>Bictegravir 50 mg</title>
            <description>Bictegravir 50 mg (2 Ã— 25 mg tablets) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O4">
            <title>Bictegravir 100 mg</title>
            <description>Bictegravir 100 mg (1 Ã— 100 mg tablet) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo matched to bictegravir tablet administered orally once daily for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>Time-Weighted Average Change From Baseline up to Day 11 (DAVG11) in Plasma HIV-1 RNA</title>
          <description>DAVG11 was defined as the time-weighted average between the first postbaseline value through the last available on-treatment (ie, the last dose date + 1) value up to Day 11 minus the baseline value in plasma HIV-1 RNA (log10 copies/mL). All HIV-1 RNA data up to Day 11 were used for this analysis. DAVG11 was calculated using the trapezoidal rule and the area-under-the-curve concept.</description>
          <population>The Per-Protocol Analysis Set included all randomized participants who took at least 1 dose of bictegravir with baseline HIV-1 RNA â‰¥ 1900 copies/mL, which allowed up to 2 log decreases in HIV-1 RNA.</population>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.26" spread="0.157"/>
                    <measurement group_id="O2" value="4.64" spread="0.498"/>
                    <measurement group_id="O3" value="4.42" spread="0.458"/>
                    <measurement group_id="O4" value="4.71" spread="1.040"/>
                    <measurement group_id="O5" value="4.50" spread="0.407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.92" spread="0.104"/>
                    <measurement group_id="O2" value="-1.33" spread="0.174"/>
                    <measurement group_id="O3" value="-1.37" spread="0.310"/>
                    <measurement group_id="O4" value="-1.61" spread="0.256"/>
                    <measurement group_id="O5" value="-0.01" spread="0.144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison was made using the t-test at a 2-sided 0.05 significance level.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison was made using the t-test at a 2-sided 0.05 significance level.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison was made using the t-test at a 2-sided 0.05 significance level.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison was made using the t-test at a 2-sided 0.05 significance level.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (AEs)</title>
        <time_frame>First dose date up to last dose date plus 30 days (Maximum: 40 days)</time_frame>
        <population>The Safety Analysis Set included participants who were randomized and received at least 1 dose of bictegravir or matched placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Bictegravir 5 mg</title>
            <description>Bictegravir 5 mg (1 Ã— 5 mg tablet) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Bictegravir 25 mg</title>
            <description>Bictegravir 25 mg (1 Ã— 25 mg tablet) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O3">
            <title>Bictegravir 50 mg</title>
            <description>Bictegravir 50 mg (2 Ã— 25 mg tablets) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O4">
            <title>Bictegravir 100 mg</title>
            <description>Bictegravir 100 mg (1 Ã— 100 mg tablet) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo matched to bictegravir tablet administered orally once daily for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (AEs)</title>
          <population>The Safety Analysis Set included participants who were randomized and received at least 1 dose of bictegravir or matched placebo.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                    <measurement group_id="O2" value="25.0"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="50.0"/>
                    <measurement group_id="O5" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Experienced Graded Laboratory Abnormalities</title>
        <description>A treatment-emergent graded laboratory abnormality was defined as an increase of at least 1 toxicity grade from predose assessment and occurring after the predose visit and on or before the date of the last dose of study drug plus 30 days. If the predose assessment was missing, then any abnormality of at least Grade 1 associated with the study drug was considered a treatment-emergent graded laboratory abnormality. The most severe graded abnormality from all tests was counted for each participant.</description>
        <time_frame>First dose date up to last dose date plus 30 days (Maximum: 40 days)</time_frame>
        <population>Participants in the Safety Analysis Set were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Bictegravir 5 mg</title>
            <description>Bictegravir 5 mg (1 Ã— 5 mg tablet) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Bictegravir 25 mg</title>
            <description>Bictegravir 25 mg (1 Ã— 25 mg tablet) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O3">
            <title>Bictegravir 50 mg</title>
            <description>Bictegravir 50 mg (2 Ã— 25 mg tablets) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O4">
            <title>Bictegravir 100 mg</title>
            <description>Bictegravir 100 mg (1 Ã— 100 mg tablet) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo matched to bictegravir tablet administered orally once daily for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced Graded Laboratory Abnormalities</title>
          <description>A treatment-emergent graded laboratory abnormality was defined as an increase of at least 1 toxicity grade from predose assessment and occurring after the predose visit and on or before the date of the last dose of study drug plus 30 days. If the predose assessment was missing, then any abnormality of at least Grade 1 associated with the study drug was considered a treatment-emergent graded laboratory abnormality. The most severe graded abnormality from all tests was counted for each participant.</description>
          <population>Participants in the Safety Analysis Set were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                    <measurement group_id="O2" value="25.0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="25.0"/>
                    <measurement group_id="O5" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Reduction From Baseline Through Day 17 in Plasma HIV-1 RNA</title>
        <description>Maximum reduction from baseline was defined as the minimum of change from baseline in plasma HIV-1 RNA (i.e. smallest change in HIV-RNA from baseline).</description>
        <time_frame>Baseline to Day 17</time_frame>
        <population>Participants in the Per-Protocol Analysis Set were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Bictegravir 5 mg</title>
            <description>Bictegravir 5 mg (1 Ã— 5 mg tablet) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Bictegravir 25 mg</title>
            <description>Bictegravir 25 mg (1 Ã— 25 mg tablet) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O3">
            <title>Bictegravir 50 mg</title>
            <description>Bictegravir 50 mg (2 Ã— 25 mg tablets) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O4">
            <title>Bictegravir 100 mg</title>
            <description>Bictegravir 100 mg (1 Ã— 100 mg tablet) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo matched to bictegravir tablet administered orally once daily for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Reduction From Baseline Through Day 17 in Plasma HIV-1 RNA</title>
          <description>Maximum reduction from baseline was defined as the minimum of change from baseline in plasma HIV-1 RNA (i.e. smallest change in HIV-RNA from baseline).</description>
          <population>Participants in the Per-Protocol Analysis Set were analyzed.</population>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.52" spread="0.079"/>
                    <measurement group_id="O2" value="-2.18" spread="0.241"/>
                    <measurement group_id="O3" value="-2.31" spread="0.191"/>
                    <measurement group_id="O4" value="-2.91" spread="0.526"/>
                    <measurement group_id="O5" value="-0.12" spread="0.177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison was made using the t-test at a 2-sided 0.05 significance level.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison was made using the t-test at a 2-sided 0.05 significance level.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison was made using the t-test at a 2-sided 0.05 significance level.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison was made using the t-test at a 2-sided 0.05 significance level.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Viral Decay Slope in Plasma HIV-1 RNA</title>
        <description>Viral Decay Slope = (log10 [HIV-1 RNA on Day x] - log10 [HIV-1 RNA on Day 1]) / (x-1), where x is the collection day of the last available on treatment HIV-1 RNA collected up to Day 7.</description>
        <time_frame>Baseline up to Day 11</time_frame>
        <population>Participants in the Per-Protocol Analysis Set were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Bictegravir 5 mg</title>
            <description>Bictegravir 5 mg (1 Ã— 5 mg tablet) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Bictegravir 25 mg</title>
            <description>Bictegravir 25 mg (1 Ã— 25 mg tablet) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O3">
            <title>Bictegravir 50 mg</title>
            <description>Bictegravir 50 mg (2 Ã— 25 mg tablets) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O4">
            <title>Bictegravir 100 mg</title>
            <description>Bictegravir 100 mg (1 Ã— 100 mg tablet) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo matched to bictegravir tablet administered orally once daily for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Decay Slope in Plasma HIV-1 RNA</title>
          <description>Viral Decay Slope = (log10 [HIV-1 RNA on Day x] - log10 [HIV-1 RNA on Day 1]) / (x-1), where x is the collection day of the last available on treatment HIV-1 RNA collected up to Day 7.</description>
          <population>Participants in the Per-Protocol Analysis Set were analyzed.</population>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.184" spread="0.0134"/>
                    <measurement group_id="O2" value="-0.252" spread="0.0277"/>
                    <measurement group_id="O3" value="-0.272" spread="0.0580"/>
                    <measurement group_id="O4" value="-0.315" spread="0.0413"/>
                    <measurement group_id="O5" value="-0.011" spread="0.0200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison was made using the t-test at a 2-sided 0.05 significance level.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison was made using the t-test at a 2-sided 0.05 significance level.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison was made using the t-test at a 2-sided 0.05 significance level.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison was made using the t-test at a 2-sided 0.05 significance level.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL</title>
        <time_frame>Day 17</time_frame>
        <population>Participants in the Per-Protocol Analysis Set were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Bictegravir 5 mg</title>
            <description>Bictegravir 5 mg (1 Ã— 5 mg tablet) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Bictegravir 25 mg</title>
            <description>Bictegravir 25 mg (1 Ã— 25 mg tablet) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O3">
            <title>Bictegravir 50 mg</title>
            <description>Bictegravir 50 mg (2 Ã— 25 mg tablets) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O4">
            <title>Bictegravir 100 mg</title>
            <description>Bictegravir 100 mg (1 Ã— 100 mg tablet) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo matched to bictegravir tablet administered orally once daily for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL</title>
          <population>Participants in the Per-Protocol Analysis Set were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="25.0"/>
                    <measurement group_id="O4" value="50.0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic (PK) Parameter: Cmax of Bictegravir Following Single-Dose and Multiple-Dose Administration</title>
        <description>Cmax is defined as the maximum concentration of drug.</description>
        <time_frame>0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 1 for single dose and Day 10 for multiple dose</time_frame>
        <population>The PK Analysis Set included all participants who were randomized and received at least 1 dose of bictegravir and had at least 1 nonmissing concentration of bictegravir.</population>
        <group_list>
          <group group_id="O1">
            <title>Bictegravir 5 mg</title>
            <description>Bictegravir 5 mg (1 Ã— 5 mg tablet) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Bictegravir 25 mg</title>
            <description>Bictegravir 25 mg (1 Ã— 25 mg tablet) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O3">
            <title>Bictegravir 50 mg</title>
            <description>Bictegravir 50 mg (2 Ã— 25 mg tablets) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O4">
            <title>Bictegravir 100 mg</title>
            <description>Bictegravir 100 mg (1 Ã— 100 mg tablet) administered orally once daily for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic (PK) Parameter: Cmax of Bictegravir Following Single-Dose and Multiple-Dose Administration</title>
          <description>Cmax is defined as the maximum concentration of drug.</description>
          <population>The PK Analysis Set included all participants who were randomized and received at least 1 dose of bictegravir and had at least 1 nonmissing concentration of bictegravir.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Single-Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="493.3" spread="72.12"/>
                    <measurement group_id="O2" value="2565.0" spread="331.31"/>
                    <measurement group_id="O3" value="4957.5" spread="667.60"/>
                    <measurement group_id="O4" value="7367.5" spread="2293.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple-Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="741.5" spread="134.65"/>
                    <measurement group_id="O2" value="3475.0" spread="712.67"/>
                    <measurement group_id="O3" value="6080.0" spread="1323.20"/>
                    <measurement group_id="O4" value="12235.0" spread="3040.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Parameter: Tmax of Bictegravir Following Single-Dose and Multiple-Dose Administration</title>
        <description>Tmax is defined as the time (observed time point) of Cmax.</description>
        <time_frame>0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 1 for single dose and Day 10 for multiple dose</time_frame>
        <population>Participants in the PK Analysis Set were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Bictegravir 5 mg</title>
            <description>Bictegravir 5 mg (1 Ã— 5 mg tablet) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Bictegravir 25 mg</title>
            <description>Bictegravir 25 mg (1 Ã— 25 mg tablet) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O3">
            <title>Bictegravir 50 mg</title>
            <description>Bictegravir 50 mg (2 Ã— 25 mg tablets) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O4">
            <title>Bictegravir 100 mg</title>
            <description>Bictegravir 100 mg (1 Ã— 100 mg tablet) administered orally once daily for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: Tmax of Bictegravir Following Single-Dose and Multiple-Dose Administration</title>
          <description>Tmax is defined as the time (observed time point) of Cmax.</description>
          <population>Participants in the PK Analysis Set were analyzed.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Single-Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="1.25"/>
                    <measurement group_id="O2" value="1.83" lower_limit="1.33" upper_limit="2.50"/>
                    <measurement group_id="O3" value="1.75" lower_limit="1.50" upper_limit="2.50"/>
                    <measurement group_id="O4" value="1.50" lower_limit="1.25" upper_limit="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple-Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" lower_limit="0.75" upper_limit="3.00"/>
                    <measurement group_id="O2" value="1.25" lower_limit="1.00" upper_limit="1.50"/>
                    <measurement group_id="O3" value="1.75" lower_limit="1.25" upper_limit="2.50"/>
                    <measurement group_id="O4" value="2.74" lower_limit="1.25" upper_limit="3.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Parameter: AUC0-24 of Bictegravir Following Single-Dose Administration</title>
        <description>AUC0-24 is defined as the concentration of drug over time from time zero to time 24 hours.</description>
        <time_frame>0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 1</time_frame>
        <population>Participants in the PK Analysis Set were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Bictegravir 5 mg</title>
            <description>Bictegravir 5 mg (1 Ã— 5 mg tablet) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Bictegravir 25 mg</title>
            <description>Bictegravir 25 mg (1 Ã— 25 mg tablet) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O3">
            <title>Bictegravir 50 mg</title>
            <description>Bictegravir 50 mg (2 Ã— 25 mg tablets) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O4">
            <title>Bictegravir 100 mg</title>
            <description>Bictegravir 100 mg (1 Ã— 100 mg tablet) administered orally once daily for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: AUC0-24 of Bictegravir Following Single-Dose Administration</title>
          <description>AUC0-24 is defined as the concentration of drug over time from time zero to time 24 hours.</description>
          <population>Participants in the PK Analysis Set were analyzed.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6262.2" spread="1432.17"/>
                    <measurement group_id="O2" value="31291.8" spread="3113.91"/>
                    <measurement group_id="O3" value="68476.5" spread="11667.41"/>
                    <measurement group_id="O4" value="94588.5" spread="27376.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Parameter: AUClast of Bictegravir Following Single-Dose Administration</title>
        <description>AUClast is defined as the concentration of drug from time zero to the last observable concentration.</description>
        <time_frame>0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 1</time_frame>
        <population>Participants in the PK Analysis Set were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Bictegravir 5 mg</title>
            <description>Bictegravir 5 mg (1 Ã— 5 mg tablet) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Bictegravir 25 mg</title>
            <description>Bictegravir 25 mg (1 Ã— 25 mg tablet) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O3">
            <title>Bictegravir 50 mg</title>
            <description>Bictegravir 50 mg (2 Ã— 25 mg tablets) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O4">
            <title>Bictegravir 100 mg</title>
            <description>Bictegravir 100 mg (1 Ã— 100 mg tablet) administered orally once daily for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: AUClast of Bictegravir Following Single-Dose Administration</title>
          <description>AUClast is defined as the concentration of drug from time zero to the last observable concentration.</description>
          <population>Participants in the PK Analysis Set were analyzed.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6295.5" spread="1496.59"/>
                    <measurement group_id="O2" value="31401.0" spread="3123.59"/>
                    <measurement group_id="O3" value="68485.6" spread="11649.37"/>
                    <measurement group_id="O4" value="94827.0" spread="27262.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Parameter: AUCtau of Bictegravir Following Multiple-Dose Administration</title>
        <description>AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).</description>
        <time_frame>0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 10</time_frame>
        <population>Participants in the PK Analysis Set were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Bictegravir 5 mg</title>
            <description>Bictegravir 5 mg (1 Ã— 5 mg tablet) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Bictegravir 25 mg</title>
            <description>Bictegravir 25 mg (1 Ã— 25 mg tablet) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O3">
            <title>Bictegravir 50 mg</title>
            <description>Bictegravir 50 mg (2 Ã— 25 mg tablets) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O4">
            <title>Bictegravir 100 mg</title>
            <description>Bictegravir 100 mg (1 Ã— 100 mg tablet) administered orally once daily for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: AUCtau of Bictegravir Following Multiple-Dose Administration</title>
          <description>AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).</description>
          <population>Participants in the PK Analysis Set were analyzed.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9983.0" spread="2664.77"/>
                    <measurement group_id="O2" value="48950.3" spread="19592.41"/>
                    <measurement group_id="O3" value="87538.4" spread="28649.77"/>
                    <measurement group_id="O4" value="178901.7" spread="31865.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Parameter: t1/2 of Bictegravir Following Multiple-Dose Administration</title>
        <description>t1/2 is defined as the estimate of the terminal elimination half-life of the drug.</description>
        <time_frame>0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 10</time_frame>
        <population>Participants in the PK Analysis Set were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Bictegravir 5 mg</title>
            <description>Bictegravir 5 mg (1 Ã— 5 mg tablet) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Bictegravir 25 mg</title>
            <description>Bictegravir 25 mg (1 Ã— 25 mg tablet) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O3">
            <title>Bictegravir 50 mg</title>
            <description>Bictegravir 50 mg (2 Ã— 25 mg tablets) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O4">
            <title>Bictegravir 100 mg</title>
            <description>Bictegravir 100 mg (1 Ã— 100 mg tablet) administered orally once daily for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: t1/2 of Bictegravir Following Multiple-Dose Administration</title>
          <description>t1/2 is defined as the estimate of the terminal elimination half-life of the drug.</description>
          <population>Participants in the PK Analysis Set were analyzed.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.79" lower_limit="17.15" upper_limit="23.80"/>
                    <measurement group_id="O2" value="15.86" lower_limit="14.07" upper_limit="19.37"/>
                    <measurement group_id="O3" value="17.84" lower_limit="15.50" upper_limit="20.51"/>
                    <measurement group_id="O4" value="20.88" lower_limit="17.91" upper_limit="24.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Parameter: Ctau of Bictegravir Following Multiple-Dose Administration</title>
        <description>Ctau is defined as the observed drug concentration at the end of the dosing interval.</description>
        <time_frame>0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 10</time_frame>
        <population>Participants in the PK Analysis Set were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Bictegravir 5 mg</title>
            <description>Bictegravir 5 mg (1 Ã— 5 mg tablet) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Bictegravir 25 mg</title>
            <description>Bictegravir 25 mg (1 Ã— 25 mg tablet) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O3">
            <title>Bictegravir 50 mg</title>
            <description>Bictegravir 50 mg (2 Ã— 25 mg tablets) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O4">
            <title>Bictegravir 100 mg</title>
            <description>Bictegravir 100 mg (1 Ã— 100 mg tablet) administered orally once daily for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: Ctau of Bictegravir Following Multiple-Dose Administration</title>
          <description>Ctau is defined as the observed drug concentration at the end of the dosing interval.</description>
          <population>Participants in the PK Analysis Set were analyzed.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="225.3" spread="84.57"/>
                    <measurement group_id="O2" value="1052.3" spread="568.90"/>
                    <measurement group_id="O3" value="2053.0" spread="977.35"/>
                    <measurement group_id="O4" value="4520.0" spread="991.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Parameter: CLss/F of Bictegravir Following Multiple-Dose Administration</title>
        <description>CLss/F is defined as the apparent oral clearance following multiple-dose administration of the drug.</description>
        <time_frame>0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 10</time_frame>
        <population>Participants in the PK Analysis Set were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Bictegravir 5 mg</title>
            <description>Bictegravir 5 mg (1 Ã— 5 mg tablet) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Bictegravir 25 mg</title>
            <description>Bictegravir 25 mg (1 Ã— 25 mg tablet) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O3">
            <title>Bictegravir 50 mg</title>
            <description>Bictegravir 50 mg (2 Ã— 25 mg tablets) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O4">
            <title>Bictegravir 100 mg</title>
            <description>Bictegravir 100 mg (1 Ã— 100 mg tablet) administered orally once daily for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: CLss/F of Bictegravir Following Multiple-Dose Administration</title>
          <description>CLss/F is defined as the apparent oral clearance following multiple-dose administration of the drug.</description>
          <population>Participants in the PK Analysis Set were analyzed.</population>
          <units>mL/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="523.8" spread="115.43"/>
                    <measurement group_id="O2" value="567.3" spread="196.72"/>
                    <measurement group_id="O3" value="621.9" spread="211.73"/>
                    <measurement group_id="O4" value="570.6" spread="87.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Parameter: AR_AUC of Bictegravir Following Multiple-Dose Administration</title>
        <description>Accumulation ratio of AUC (AR_AUC) = AUCtau on Day 10 / AUC0-24 on Day 1. Percentage of accumulation ratio has been reported.</description>
        <time_frame>0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 1 and 10</time_frame>
        <population>Participants in the PK Analysis Set were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Bictegravir 5 mg</title>
            <description>Bictegravir 5 mg (1 Ã— 5 mg tablet) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Bictegravir 25 mg</title>
            <description>Bictegravir 25 mg (1 Ã— 25 mg tablet) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O3">
            <title>Bictegravir 50 mg</title>
            <description>Bictegravir 50 mg (2 Ã— 25 mg tablets) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O4">
            <title>Bictegravir 100 mg</title>
            <description>Bictegravir 100 mg (1 Ã— 100 mg tablet) administered orally once daily for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: AR_AUC of Bictegravir Following Multiple-Dose Administration</title>
          <description>Accumulation ratio of AUC (AR_AUC) = AUCtau on Day 10 / AUC0-24 on Day 1. Percentage of accumulation ratio has been reported.</description>
          <population>Participants in the PK Analysis Set were analyzed.</population>
          <units>percentage of AR_AUC</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160.2" spread="25.86"/>
                    <measurement group_id="O2" value="157.4" spread="59.76"/>
                    <measurement group_id="O3" value="125.3" spread="20.92"/>
                    <measurement group_id="O4" value="193.3" spread="22.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Parameter: AR_Cmax of Bictegravir Following Multiple-Dose Administration</title>
        <description>Accumulation ratio of Cmax (AR_Cmax) = Cmax on Day 10 / Cmax on Day 1. Percentage of accumulation ratio has been reported.</description>
        <time_frame>0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 1 and 10</time_frame>
        <population>Participants in the PK Analysis Set were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Bictegravir 5 mg</title>
            <description>Bictegravir 5 mg (1 Ã— 5 mg tablet) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Bictegravir 25 mg</title>
            <description>Bictegravir 25 mg (1 Ã— 25 mg tablet) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O3">
            <title>Bictegravir 50 mg</title>
            <description>Bictegravir 50 mg (2 Ã— 25 mg tablets) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O4">
            <title>Bictegravir 100 mg</title>
            <description>Bictegravir 100 mg (1 Ã— 100 mg tablet) administered orally once daily for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: AR_Cmax of Bictegravir Following Multiple-Dose Administration</title>
          <description>Accumulation ratio of Cmax (AR_Cmax) = Cmax on Day 10 / Cmax on Day 1. Percentage of accumulation ratio has been reported.</description>
          <population>Participants in the PK Analysis Set were analyzed.</population>
          <units>percentage of AR_Cmax</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149.8" spread="6.61"/>
                    <measurement group_id="O2" value="138.5" spread="37.40"/>
                    <measurement group_id="O3" value="122.0" spread="13.31"/>
                    <measurement group_id="O4" value="168.4" spread="16.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK/Pharmacodynamic (PD) Analysis: Pearson Correlation Between AUCtau of Bictegravir and DAVG11 in Plasma HIV-1 RNA</title>
        <description>AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval). DAVG11 was defined as the time-weighted average between the first postbaseline value through the last available on-treatment (ie, the last dose date + 1) value up to Day 11 minus the baseline value in plasma HIV-1 RNA (log10 copies/mL).</description>
        <time_frame>0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Day 10</time_frame>
        <population>The PK/PD Analysis Set included all participants in PP Analysis Set (all randomized participants who took at least 1 dose of bictegravir with baseline HIV-1 RNA â‰¥ 1900 copies/mL, which allowed up to 2 log decreases in HIV-1 RNA) and had both nonmissing bictegravir AUCtau on Day 10 and DAVG11 in log10 plasma HIV-1 RNA.</population>
        <group_list>
          <group group_id="O1">
            <title>Bictegravir 5 mg</title>
            <description>Bictegravir 5 mg (1 Ã— 5 mg tablet) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Bictegravir 25 mg</title>
            <description>Bictegravir 25 mg (1 Ã— 25 mg tablet) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O3">
            <title>Bictegravir 50 mg</title>
            <description>Bictegravir 50 mg (2 Ã— 25 mg tablets) administered orally once daily for 10 days</description>
          </group>
          <group group_id="O4">
            <title>Bictegravir 100 mg</title>
            <description>Bictegravir 100 mg (1 Ã— 100 mg tablet) administered orally once daily for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>PK/Pharmacodynamic (PD) Analysis: Pearson Correlation Between AUCtau of Bictegravir and DAVG11 in Plasma HIV-1 RNA</title>
          <description>AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval). DAVG11 was defined as the time-weighted average between the first postbaseline value through the last available on-treatment (ie, the last dose date + 1) value up to Day 11 minus the baseline value in plasma HIV-1 RNA (log10 copies/mL).</description>
          <population>The PK/PD Analysis Set included all participants in PP Analysis Set (all randomized participants who took at least 1 dose of bictegravir with baseline HIV-1 RNA â‰¥ 1900 copies/mL, which allowed up to 2 log decreases in HIV-1 RNA) and had both nonmissing bictegravir AUCtau on Day 10 and DAVG11 in log10 plasma HIV-1 RNA.</population>
          <units>correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.000"/>
                    <measurement group_id="O2" value="0.275"/>
                    <measurement group_id="O3" value="-0.940"/>
                    <measurement group_id="O4" value="0.713"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First dose date up to last dose date plus 30 days (Maximum: 40 days)</time_frame>
      <desc>The Safety Analysis Set included participants who were randomized and received at least 1 dose of bictegravir or matched placebo.</desc>
      <group_list>
        <group group_id="E1">
          <title>Bictegravir 5 mg</title>
          <description>Bictegravir 5 mg (1 Ã— 5 mg tablet) administered orally once daily for 10 days</description>
        </group>
        <group group_id="E2">
          <title>Bictegravir 25 mg</title>
          <description>Bictegravir 25 mg (1 Ã— 25 mg tablet) administered orally once daily for 10 days</description>
        </group>
        <group group_id="E3">
          <title>Bictegravir 50 mg</title>
          <description>Bictegravir 50 mg (2 Ã— 25 mg tablets) administered orally once daily for 10 days</description>
        </group>
        <group group_id="E4">
          <title>Bictegravir 100 mg</title>
          <description>Bictegravir 100 mg (1 Ã— 100 mg tablet) administered orally once daily for 10 days</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Placebo matched to bictegravir tablet administered orally once daily for 10 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Papule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:&#xD;
The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or&#xD;
The study has been completed at all study sites for at least 2 years</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gilead Clinical Study Information Center</name_or_title>
      <organization>Gilead Sciences</organization>
      <phone>1-833-445-3230 (GILEAD-0)</phone>
      <email>GileadClinicalTrials@gilead.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

